|Outpatient Evaluation and Management of Coronavirus Disease 2019
|Wang, Pao Shan
Cheng, Kuo Chen
|Journal of Internal Medicine of Taiwan
An outbreak of SARS-CoV-2 Omicron variant infection occurred in Taiwan since April 2022. With Omicron infection, upper respiratory symptoms appear to be more common and the risk of severe disease or death is lower than prior variants. Outpatient management and home care are appropriate for most patients with mild COVID-19. The outpatient evaluation with COVID-19 is to assess the severity of symptoms, the safety of home care, the risk for progression to severe disease and to determine appropriateness antiviral agent of COVID-19. For symptomatic outpatients with risk for progression to severe disease, Nirmatrelvlr/ritonavlr or molnupiravir are preferred options for COVID-19 therapy, which reduces the risk of hospitalization and mortality in outpatients with mild disease and associated risk factors. If patients developed warning signs of severe COVID-19, they should visit emergency medical care immediately.
|Appears in Collections:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.